🌾 Doxycycline Treatment Course Simulator

When Treatment Begins After the Bite

Placeholder: earlier treatment start improves outcomes.

• ~5 d: Median bite-to-treatment (Placeholder figure)
• ~95%: Early-stage cure rate (Placeholder figure)
• ~65%: Delayed-stage cure rate (Placeholder figure)
• 3–30 d: Erythema migrans window (Placeholder figure)

Why timing matters

Placeholder: short paragraph on dissemination risk over time.

Early Spirochete Clearance Window

Placeholder: first five days show the steepest load decline.

• ~60%: Day-5 load reduction (Placeholder figure)
• ~2 h: Peak plasma conc. (Placeholder figure)
• ~18 h: Half-life (Placeholder figure)
• 2x/day: Dosing frequency (Placeholder figure)

Early pharmacodynamics

Placeholder: short paragraph on bactericidal action.

Continued Clearance Through Mid-Course

Placeholder: sustained dosing continues reducing residual burden.

• ~90%: Day-14 load reduction (Placeholder figure)
• ~70%: Symptom resolution (Placeholder figure)
• High: Adherence importance (Placeholder figure)
• 14 d: Typical course (early) (Placeholder figure)

Mid-course dynamics

Placeholder: short paragraph on adherence and dosing.

Completing Disseminated-Stage Courses

Placeholder: disseminated cases require the full 21-day course.

• 21 d: Disseminated course (Placeholder figure)
• ~15%: Late-stage load floor (Placeholder figure)
• Elevated: Relapse risk if short (Placeholder figure)
• Possible: Neuro involvement (Placeholder figure)

Why longer courses help

Placeholder: short paragraph on disseminated-stage duration.

Cure Probability by Stage and Duration

Placeholder: final cure probability combines stage and course length.

• ~98%: Best-case cure (Placeholder figure)
• ~30%: Worst-case cure (Placeholder figure)
• Strong: Course-length effect (Placeholder figure)
• Strong: Stage effect (Placeholder figure)

Reading the gauge

Placeholder: short paragraph on interpreting the outcome gauge.

Placeholder: short callout on matching course length to disease stage.